Envoy Medical, Inc.
COCHNASDAQHealthcare● Active
$0.66
$-0.00(-0.33%)
Market Cap$13707200
P/E Ratio—
52W High$1.89
52W Low$0.363
Envoy Medical, Inc. (COCH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
COCH · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.11
Est. -$0.14 · +21.4%
Revenue
$0.00B
Est. $0.00B · -61.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
COCH reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$0.08 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.14 | -$0.11 | +21.4% | $0.00B | $0.00B | -61.0% |
| ▼ Q1 FY2026 | Mar 23, 2026 | -$0.24 | -$0.26 | -8.3% | $0.00B | $0.00B | +233.3% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.27 | -$0.35 | -29.6% | $0.00B | $0.00B | -30.0% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -$0.29 | -$0.32 | -10.3% | $0.00B | $0.00B | +17.7% |
| ▲ Q2 FY2025 | May 1, 2025 | -$0.35 | -$0.29 | +17.1% | $0.00B | $0.00B | -29.2% |
| ▼ Q1 FY2025 | Mar 28, 2025 | -$0.33 | -$0.45 | -36.4% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.27 | -$0.37 | -37.0% | $0.00B | $0.00B | -25.3% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.11
EPS Est.
-$0.14
EPS Surpr.
+21.4%
Revenue
$0.00B
Q1 FY2026
Mar 23, 2026Miss
EPS Actual
-$0.26
EPS Est.
-$0.24
EPS Surpr.
-8.3%
Revenue
$0.00B
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.35
EPS Est.
-$0.27
EPS Surpr.
-29.6%
Revenue
$0.00B
Q3 FY2025
Jul 31, 2025Miss
EPS Actual
-$0.32
EPS Est.
-$0.29
EPS Surpr.
-10.3%
Revenue
$0.00B
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$0.29
EPS Est.
-$0.35
EPS Surpr.
+17.1%
Revenue
$0.00B
Q1 FY2025
Mar 28, 2025Miss
EPS Actual
-$0.45
EPS Est.
-$0.33
EPS Surpr.
-36.4%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.37
EPS Est.
-$0.27
EPS Surpr.
-37.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q3 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q2 FY2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q1 FY2026 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q4 FY2025 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q3 FY2025 | $-0.27 | $-0.24 | $-0.21 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +21.4% | $0.65 | $0.64 | -0.23% |
| ▼ Q1 FY2026 | Mar 23, 2026 | -8.3% | $0.78 | $0.75 | -3.37% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -29.6% | $0.70 | $0.70 | -0.34% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -10.3% | $1.56 | $1.46 | -6.41% |
| ▲ Q2 FY2025 | May 1, 2025 | +17.1% | $1.42 | $1.38 | -2.82% |
| ▼ Q1 FY2025 | Mar 28, 2025 | -36.4% | $1.39 | $1.36 | -2.16% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -37.0% | $1.96 | $2.13 | +8.67% |
| ▼ Q3 FY2024 | Aug 12, 2024 | -12.5% | $2.26 | $2.70 | +19.47% |
Q2 FY2026-0.23%
Report Date
May 11, 2026
EPS Beat/Miss
+21.4%
Price Before
$0.65
Price After
$0.64
Q1 FY2026-3.37%
Report Date
Mar 23, 2026
EPS Beat/Miss
-8.3%
Price Before
$0.78
Price After
$0.75
Q4 FY2025-0.34%
Report Date
Nov 10, 2025
EPS Beat/Miss
-29.6%
Price Before
$0.70
Price After
$0.70
Q3 FY2025-6.41%
Report Date
Jul 31, 2025
EPS Beat/Miss
-10.3%
Price Before
$1.56
Price After
$1.46
Q2 FY2025-2.82%
Report Date
May 1, 2025
EPS Beat/Miss
+17.1%
Price Before
$1.42
Price After
$1.38
Q1 FY2025-2.16%
Report Date
Mar 28, 2025
EPS Beat/Miss
-36.4%
Price Before
$1.39
Price After
$1.36
Q4 FY2024+8.67%
Report Date
Nov 14, 2024
EPS Beat/Miss
-37.0%
Price Before
$1.96
Price After
$2.13
Q3 FY2024+19.47%
Report Date
Aug 12, 2024
EPS Beat/Miss
-12.5%
Price Before
$2.26
Price After
$2.70
Avg Beat Reaction-1.52%
Avg Miss Reaction+2.64%
Beat Rate2 / 8 quarters
Largest Move+19.47% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: COCH ends December
Envoy Medical, Inc. (COCH) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.11 — beating the analyst consensus of $-0.14 by +21.4%. The next COCH earnings date is expected around September 1, 2026.
Each quarter, investors track COCH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. COCH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
COCH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
COCH earnings · 5 questionsEnvoy Medical, Inc.'s next earnings report is expected around September 1, 2026. COCH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; COCH historically reports after market close (AMC).
COCH earnings datewhen is COCH earningsCOCH next earnings datewhen does COCH report earningsCOCH earnings calendar
▸ Source: FMP · Envoy Medical, Inc. SEC filings · US GAAP · Envoy Medical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026